Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.33 |
| ▸ | KDM6A | O15550 | 1/20 | 0.32 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7096696 | 0.82 | GPR119 (0.46) | GPR119SCN9A | |
| SCHEMBL6322500 | 0.67 | ELANE (0.32) | — | |
| SCHEMBL7258834 | 0.65 | HRH3 (0.35) | HRH3PTPN2PTPN1PTPN6 | |
| SCHEMBL5898783 | 0.63 | NFKB1 (0.36) | — | |
| SCHEMBL5898780 | 0.63 | NFKB1 (0.36) | — | |
| SCHEMBL3733177 | 0.63 | FPR2 (0.42) | PTPN2PTPN1PTPN6KDM4E | |
| SCHEMBL4869543 | 0.63 | CTSK (0.47) | — | |
| SCHEMBL4870463 | 0.63 | CTSK (0.47) | — | |
| SCHEMBL4861261 | 0.63 | CTSK (0.47) | — | |
| SCHEMBL4478908 | 0.63 | CTSK (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232820-A1 | Method for synthesizing oxazinones | WOLFE SAUL (CA) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232820-A1 | Method for synthesizing oxazinones | DHPS, HSD17B12, PNPO | HRH3 3973/4885GPR119 3278/4885PTPN2 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.